Liposome-Based Pathogen Neutralizing Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the functional immune status of patients, particularly during pandemics like COVID-19, are slow, expensive, and require specialized labs, as they rely on cell culture tests that are not readily available or practical for rapid, low-cost assessment of pathogen-neutralizing antibodies.
Innovation Solution
A particle collection comprising pathogen-mimicking particles, pathogen-targeting particles, and complement activating agents is used to detect pathogen-neutralizing molecules, allowing for a rapid and cost-effective method to determine the presence of neutralizing antibodies in a sample, which can be performed in a point-of-care setting using a kit or device.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell culture tests are used to detect pathogen-neutralizing molecules, then measurement precision is improved, but time consumption increases and device complexity increases
Solution Approach 1:
The patent uses virus-like particles (VLPs) as non-infectious copies of actual pathogens to mimic pathogen structure and function. These VLPs can be detected by neutralizing antibodies without requiring live virus infection, enabling rapid detection in 15-30 minutes without the time-consuming cell culture infection cycle
Solution Approach 2:
The patent extracts and isolates the essential detection function from complex cell culture systems. By using VLPs bound to complement activating agents, the assay separates the neutralization detection step from the infection process, allowing direct detection of neutralizing antibodies in patient samples without needing living cells or complex biosafety facilities
2Measurement precision
If cell culture tests are used to detect pathogen-neutralizing molecules, then measurement precision is improved, but device complexity increases
Solution Approach 1:
The patent replaces complex living virus systems with artificial virus-like particles that replicate the essential surface features and complement activating properties without requiring biosafety level 2 or 3 facilities. This copying approach maintains detection accuracy while eliminating the need for specialized laboratory infrastructure
Solution Approach 2:
The patent introduces complement activating agents as intermediary molecules that bridge the detection system and the patient sample. These agents enable the assay to function in simple laboratory settings by mediating the interaction between VLPs and neutralizing antibodies, eliminating the need for complex cell culture systems and specialized biosafety equipment
3Ease of operation
If ELISA or lateral flow assay are used to quantify binding antibodies, then ease of operation is improved, but measurement precision deteriorates
Solution Approach 1:
The patent uses VLPs as simplified copies of pathogens that can be detected by standard immunoassay techniques. These VLPs maintain the essential neutralization function while being compatible with simple assay formats, providing both ease of operation and functional measurement precision
Solution Approach 2:
The patent applies local quality by concentrating the complement activating agent at specific locations on the VLP surface. This localized placement ensures that only VLPs bound to neutralizing antibodies trigger the detection signal, maintaining assay simplicity while providing accurate functional measurement of neutralization capacity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid, reliable detection of pathogen-neutralizing molecules, providing functional insights into a patient's immune status without the need for specialized equipment or facilities, facilitating timely assessment of immunity to pathogens like SARS-CoV-2.
Implementation Method 1
a pathogen-targeting particle, preferably a liposome, wherein said pathogen-targeting particle comprises at least one pathogen-targeting molecule, wherein said pathogen-targeting molecule is capable of binding, preferably specifically binding, to said biomarker of said pathogen
Data Source
AI summary
The present invention relates to a particle collection for detecting a pathogen-neutralizing molecule. The present invention further relates to a composition comprising a particle collection. The present invention also relates to a method of detecting a pathogen-neutralizing molecule. Furthermore, the present invention relates to a kit for detecting a pathogen-neutralizing molecule. The present invention further relates to a point-of-care device, and to a use of a particle collection or a composition in a method of detecting a pathogen-neutralizing molecule.